3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Thrombocytopenia
4
Leukemia, Myeloid, Acute
4
Leukemia
3
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Jacobs syndrome
1
Congenital Abnormalities
1
Bone Neoplasms
1
Interventions
Rituximab
30
Cyclophosphamide
18
fludarabine phosphate
14
Filgrastim
12
Mycophenolic Acid
11
Antilymphocyte Serum
11
Cyclosporine
10
Whole-Body Irradiation
9
Bortezomib
9
Tacrolimus
8
Radiotherapy
8
Peripheral Blood Stem Cell Transplantation
8
Methotrexate
6
Lenalidomide
6
Cord Blood Stem Cell Transplantation
6
Busulfan
6
Granulocyte Colony-Stimulating Factor
5
venetoclax
4
tanespimycin
4
Polymerase Chain Reaction
4
Methylprednisolone
4
Melphalan
4
Flow Cytometry
4
Etoposide
4
Bendamustine Hydrochloride
4
ublituximab
3
thymoglobulin
3
pembrolizumab
3
ibritumomab tiuxetan
3
fludarabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, B-Cell, Marginal Zone
×
eltrombopag
×
Clear all
NCT01500538
2016-02-15
VEIL
Peter MacCallum Cancer Centre, Australia
Phase 2
Terminated
1 enrolled